Dr George Lee returns to discuss the latest medical news. Expect deep insights delivered with generous humour. Earlier this week, the Health Ministry announced  that it has approved the biosimilar version of trastuzumab, a targeted therapy for women with HER2-positive breast cancer. The biosimilar version will significantly reduce the cost of treatment, which currently costs RM130,000 a year. Datin Paduka Prof Dr Teo Soo Hwang, CEO of Cancer Research Malaysia, joins us to discuss how biosimilar therapies can improve accessibility to cancer care.

Produced by: Tee Shiao Eek

Presented by: Meera Sivasothy

This and more than 60,000 other podcasts in your hand. Download the all new BFM mobile app.

Categories:  Health Policy,  Diseases and Conditions,  Mental Health,  Healthy Living,  Fitness,  Science,  Medical Innovation and Technology

Tags:  breast cancer,  herceptin,  tumour,  chemotherapy,  health and living,  the bigger picture,